Connect Biopharma (CNTB) news
Recent news
Connect Biopharma Holdings Ltd: BTIG cuts target price to $5 from $10
AInvest Wire · Oct 1, 2026Connect Biopharma - Rademikibart reduced treatment failure rate by 81% through one month in phase 2 study
Connect Biopharma recently reported positive results from a phase 2 clinical trial of its investigational drug, Rademikibart, for the treatment of atopic dermatitis. The study demonstrated that the treatment reduced the rate of treatment failure by 81% over a one-month period. This outcome…
AInvest Wire · Sep 30, 2026Connect Biopharma - To engage FDA for phase 3 program for Rademikibart in COPD
AInvest Wire · Sep 30, 2026Connect Biopharma - Rademikibart reduced new moderate to severe COPD exacerbations by 85% through one month
AInvest Wire · Sep 30, 2026Connect Biopharma Holdings Ltd: Oppenheimer cuts target price to $5 from $8
Oppenheimer has revised its target price for Connect Biopharma Holdings Ltd (NASDAQ: CNCT) from $8 to $5, reflecting a 37.5% reduction in its valuation outlook for the company. The adjustment follows a reassessment of the firm’s near-term clinical and commercial prospects, according to the firm’s…
AInvest Wire · Sep 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.